<DOC>
	<DOCNO>NCT02452151</DOCNO>
	<brief_summary>The objective study compare efficacy Infliximab-Biosimilar Infliximab-Innovator demonstrate noninferiority , patient ulcerative colitis Crohn 's disease remission treatment infliximab 3 month .</brief_summary>
	<brief_title>`` Efficacy Safety Infliximab-biosimilar ( Inflectra ) Compared Infliximab-innovator ( Remicade ) Patients With Inflammatory Bowel Disease Remission : SIMILAR Trial ''</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients , male female , age 18 year time enrolment select hospital database base appointment Infliximab infusion treatment IBD . Patients eligible inclusion establish diagnosis ulcerative colitis Crohn 's disease , clinical remission medically treat Infliximab least 12 week prior inclusion . 1 . Patient allergy hypersensitivity one component infliximab and/or immunoglobulin product , except hypersensitivity reaction positive response hydrocortisone thereby control . 2 . Patient current diagnosis hepatitis B , hepatitis C infection human immunodeficiency virus ( HIV ) 1 2 . Patients past history chronic hepatitis B hepatitis C exclude . 3 . Patient history tuberculosis ( TB ) current diagnosis TB severe chronic infection abscess , opportunistic infection invasive fungal infection . Patients past history severe chronic infection exclude . 4 . Patient recent exposure person active TB . In case screen latent TB ( define positive result interferonÎ³ release assay ( IGRA ) negative examination chest Xray ) perform . If sufficient documentation prophylaxis complete resolution follow TBtreatment base hospitalspecific guideline patient enrol . If result IGRA indeterminate screening , 1 retest do . If repeat IGRA result indeterminate , patient exclude . Patients positive IGRA result negative examination chest Xray receive least first 30 day TBtherapy enrol . 5 . Patient take follow concomitant medication treatment : Corticosteroids ( prednisone , prednisolone budosenide ) . Live liveattenuated vaccine within 8 week randomization . Any biological treatment infliximab . Subtotal total colectomy prior randomization . Any planned abdominal surgery IBD time randomization and/or study period . 6 . Patient one follow medical condition : Active enterovesical , enteroretroperitoneal , enterocutaneous enterovaginal fistula within 6 month prior screen . Enteroenteral fistula without clinical significant symptom upon investigator 's opinion anal fistula without drain problem allow . Current short bowel syndrome . History malignancy within 5 year prior randomization except cutaneous basal cell carcinoma , cutaneous squamous cell carcinoma completely excise cure squamous carcinoma uterine cervix . History lymphoma lymphproliferative disease bone marrow hyperplasia . New York Heart Association ( NYHA ) class III IV heart failure . History organ transplantation , include corneal graft/transplantation . 7 . Patient treatment investigational device medical product within 4 week randomization 5 halflives , whichever longer . 8 . Female patient currently pregnant , breastfeed plan become pregnant breastfeed within 6 month last dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Inflectra</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Biosimilar</keyword>
</DOC>